Lotta Hansson

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 7

Top Venues

European journal of haematology

Leukemia

EJHaem

British journal of haematology

Karolinska Universitetssjukhuset

Karolinska Institutet (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Karolinska Universitetssjukhuset

Sweden

Senior Consultant, Oncology :: Hematology Center

Education History

Karolinska Institutet - Mar 12 2004

Sweden

PHD :: Oncology-Pathology

Publications

Maria L Andersson, Hemming Johansson, Anders Österborg, Agneta Månsson-Broberg, Lotta Hansson, Marzia Palma
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib-A retrospective analysis on consecutive patients from a well-defined region. European journal of haematology (2023)
Agnes Mattsson, Sandra Eketorp Sylvan, Per Axelsson, Fredrik Ellin, Christian Kjellander, Karin Larsson, Birgitta Lauri, Catharina Lewerin, Christian Scharenberg, Love Tätting, Hemming Johansson, Anders Österborg, Lotta Hansson
Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients. European journal of haematology (2023)
Lisa Blixt, Yu Gao, David Wullimann, Hanna Murén Ingelman-Sundberg, Sandra Muschiol, Katie Healy, Gordana Bogdanovic, Elisa Pin, Peter Nilsson, Christian Kjellander, Alba Grifoni, Alessandro Sette, Margaret Sällberg Chen, Hans-Gustaf Ljunggren, Marcus Buggert, Lotta Hansson, Anders Österborg
Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination. Blood 140 (22) (2022)
Jeanette Lundin, Tom A Mulder, Magdalena Kättström, Tove Wästerlid, Anders Uddevik, Håkan Mellstedt, Kia Heimersson, Lotta Hansson, Marzia Palma, Anders Österborg
Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia. EJHaem 2 (3) (2021)
Lisa Blixt, Gordana Bogdanovic, Marcus Buggert, Yu Gao, Sophia Hober, Katie Healy, Hemming Johansson, Christian Kjellander, Sára Mravinacová, Sandra Muschiol, Peter Nilsson, Marzia Palma, Elisa Pin, Carl Inge Edvard Smith, Olga Stromberg, Margaret Sällberg Chen, Rula Zain, Lotta Hansson, Anders Österborg
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients. Leukemia (2021)
Agnes Mattsson, Sandra E Sylvan, Anna Asklid, Joel Wiggh, Maria Winqvist, Jeanette Lundin, Larry Mansouri, Richard Rosenquist, Hemming Johansson, Anders Österborg, Lotta Hansson
Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients. British journal of haematology 191 (3) (2020)
Marzia Palma, Lotta Hansson, Tom A Mulder, Lars Adamson, Barbro Näsman-Glaser, Ingrid Eriksson, Kia Heimersson, Harriet Ryblom, Fariba Mozaffari, Ann Svensson, Giusy Gentilcore, Anders Österborg, Håkan Mellstedt
Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients. European journal of haematology 101 (1) (2018)

Lotta Hansson.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Lotta Hansson